Champions Oncology
Market Cap
US$150.1m
Last Updated
2021/01/15 00:48 UTC
Data Sources
Company Financials +
Executive Summary
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Champions Oncology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CSBR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CSBR's weekly volatility (9%) has been stable over the past year.
Market Performance
7 Day Return
0.7%
CSBR
0.8%
US Life Sciences
0.6%
US Market
1 Year Return
31.7%
CSBR
45.0%
US Life Sciences
21.0%
US Market
Return vs Industry: CSBR underperformed the US Life Sciences industry which returned 45% over the past year.
Return vs Market: CSBR exceeded the US Market which returned 21% over the past year.
Shareholder returns
| CSBR | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.7% | 0.8% | 0.6% |
| 30 Day | -1.5% | 7.4% | 4.2% |
| 90 Day | 24.6% | 13.6% | 12.4% |
| 1 Year | 31.7%31.7% | 45.2%45.0% | 23.7%21.0% |
| 3 Year | 182.2%182.2% | 110.7%109.4% | 47.4%37.6% |
| 5 Year | 207.7%207.7% | 234.3%230.1% | 131.6%105.9% |
Long-Term Price Volatility Vs. Market
How volatile is Champions Oncology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?3 weeks ago | Simply Wall St
Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares4 weeks ago | Simply Wall St
Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent ResultsValuation
Is Champions Oncology undervalued compared to its fair value and its price relative to the market?
40.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CSBR ($11.23) is trading below our estimate of fair value ($18.93)
Significantly Below Fair Value: CSBR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CSBR is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: CSBR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CSBR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CSBR is overvalued based on its PB Ratio (21.8x) compared to the US Life Sciences industry average (8.5x).
Next Steps
Future Growth
How is Champions Oncology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
172.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSBR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CSBR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CSBR's is expected to become profitable in the next 3 years.
Revenue vs Market: CSBR's revenue (17.8% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: CSBR's revenue (17.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Champions Oncology performed over the past 5 years?
57.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSBR is currently unprofitable.
Growing Profit Margin: CSBR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CSBR is unprofitable, but has reduced losses over the past 5 years at a rate of 57.1% per year.
Accelerating Growth: Unable to compare CSBR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSBR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (30.4%).
Return on Equity
High ROE: CSBR has a negative Return on Equity (-22.7%), as it is currently unprofitable.
Next Steps
Financial Health
How is Champions Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: CSBR's short term assets ($15.0M) exceed its short term liabilities ($12.8M).
Long Term Liabilities: CSBR's short term assets ($15.0M) exceed its long term liabilities ($6.1M).
Debt to Equity History and Analysis
Debt Level: CSBR is debt free.
Reducing Debt: CSBR has no debt compared to 5 years ago when its debt to equity ratio was 0.05%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CSBR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CSBR is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 50.5% per year.
Next Steps
Dividend
What is Champions Oncology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CSBR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CSBR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CSBR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CSBR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSBR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Ronnie Morris (54 yo)
4yrs
Tenure
US$1,343,653
Compensation
Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris previously served as the President and a Director of Champions Oncology, Inc. from Oc...
CEO Compensation Analysis
Compensation vs Market: Ronnie's total compensation ($USD1.34M) is above average for companies of similar size in the US market ($USD1.02M).
Compensation vs Earnings: Ronnie's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4yrs | US$1.34m | 1.92% $ 2.9m | |
| Chief Financial Officer | 7.58yrs | US$372.92k | 0% $ 0 | |
| Chief Strategy & Innovation Officer and Director | 4.75yrs | US$34.18k | 0% $ 0 | |
| Vice President of Scientific Operations | 2yrs | no data | no data | |
| Chief Commercial Officer | no data | no data | no data |
3.0yrs
Average Tenure
54yo
Average Age
Experienced Management: CSBR's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4yrs | US$1.34m | 1.92% $ 2.9m | |
| Chief Strategy & Innovation Officer and Director | 4.75yrs | US$34.18k | 0% $ 0 | |
| Independent Director | 9.58yrs | US$41.02k | 0% $ 0 | |
| Chairman of the Board | 4yrs | US$68.37k | 5.43% $ 8.2m | |
| Independent Lead Director | 4.17yrs | US$34.18k | 5.6% $ 8.4m | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 7.83yrs | US$41.02k | 0.92% $ 1.4m | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 12.83yrs | US$41.02k | 0.45% $ 675.5k | |
| Board Observer | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
7.8yrs
Average Tenure
55yo
Average Age
Experienced Board: CSBR's board of directors are considered experienced (7.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CSBR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.1%.
Top Shareholders
Company Information
Champions Oncology, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Champions Oncology, Inc.
- Ticker: CSBR
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$150.134m
- Shares outstanding: 13.37m
- Website: https://www.championsoncology.com
Number of Employees
Location
- Champions Oncology, Inc.
- One University Plaza
- Suite 307
- Hackensack
- New Jersey
- 7601
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CSBR | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Nov 1988 |
| 2I3 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 1988 |
Biography
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approac...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/15 00:48 |
| End of Day Share Price | 2021/01/14 00:00 |
| Earnings | 2020/10/31 |
| Annual Earnings | 2020/04/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.